Mori M, Kobayashi I, Shimoyama S, Uehara T, Nemoto T
Endocrinol Jpn. 1977 Apr;24(2):149-53. doi: 10.1507/endocrj1954.24.149.
The effect of chronic administration of sulpiride on serum human growth hormone (hGH), prolactin and thyroid stimulating hormone (TSH) was examined in 6 normal subjects. Sulpiride was given orally at a dose of 300 mg (t.i.d.) for 30 days. Sulpiride raised serum prolactin levels in all subjects examined. In addition, sulpiride suppressed hGH release induced by L-dopa, although the basal hGH level was not changed. Sulpiride treatment appeared to antagonize partially the inhibitory effect of L-dopa on prolactin release. Following thyrotropin-releasing hormone (TRH) injection, the percent increment in prolactin levels from the baseline in sulpiride-treated subjects was less than in controls without sulpiride. In contrast, both the basal and TRH-stimulated TSH levels were not influenced by sulpiride. These observations suggest that sulpiride suppresses L-dopa-induced hGH release and stimulates prolactin release, presumably by acting against the dopaminergic mechanism either on the hypothalamus or on the pituitary. The decreased prolactin response to TRH after sulpiride treatment may indicate a diminished reserve capacity in pituitary prolactin release.
在6名正常受试者中研究了长期服用舒必利对血清人生长激素（hGH）、催乳素和促甲状腺激素（TSH）的影响。舒必利以300毫克（每日三次）的剂量口服给药，持续30天。舒必利使所有受试对象的血清催乳素水平升高。此外，舒必利抑制了左旋多巴诱导的hGH释放，尽管基础hGH水平未发生变化。舒必利治疗似乎部分拮抗了左旋多巴对催乳素释放的抑制作用。注射促甲状腺激素释放激素（TRH）后，舒必利治疗组受试者催乳素水平相对于基线的升高百分比低于未服用舒必利的对照组。相反，基础TSH水平和TRH刺激后的TSH水平均不受舒必利影响。这些观察结果表明，舒必利抑制左旋多巴诱导的hGH释放并刺激催乳素释放，推测是通过作用于下丘脑或垂体的多巴胺能机制。舒必利治疗后催乳素对TRH的反应降低可能表明垂体催乳素释放的储备能力下降。
